Role of aspirin in primary prevention of cardiovascular disease

Role of aspirin in primary prevention of cardiovascular disease

The benefits of aspirin therapy for the secondary prevention of cardiovascular disease clearly outweigh the risks of bleeding, and low-dose aspirin is uniformly recommended in this setting. However, no clear consensus exists about whether, and if so in whom, aspirin therapy is appropriate for the pr...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Patrono, C, Baigent, C
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Springer Nature 2019

Eitemau Tebyg

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
gan: Baigent, C, et al.
Cyhoeddwyd: (2003)

Low-dose aspirin for the prevention of atherothrombosis.
gan: Patrono, C, et al.
Cyhoeddwyd: (2005)

Drug therapy - Low-dose aspirin for the prevention of atherothrombosis
gan: Patrono, C, et al.
Cyhoeddwyd: (2005)

Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
gan: Patrono, C, et al.
Cyhoeddwyd: (2010)

Prevention. Aspirin in primary prevention--good news and bad news.
gan: Hennekens, C, et al.
Cyhoeddwyd: (2012)

Prevention: Aspirin in primary prevention-good news and bad news
gan: Hennekens, C, et al.
Cyhoeddwyd: (2012)

Aspirin in the primary prevention of vascular disease Reply
gan: Baigent, C, et al.
Cyhoeddwyd: (2009)

Aspirin in the primary prevention of vascular disease Reply
gan: Baigent, C, et al.
Cyhoeddwyd: (2009)

Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
gan: Patrono, C, et al.
Cyhoeddwyd: (2009)

Aspirin overutilization for the primary prevention of cardiovascular disease
gan: VanWormer JJ, et al.
Cyhoeddwyd: (2014-12-01)

Aspirin for primary prevention of cardiovascular disease in diabetes
gan: Ying Xing, et al.
Cyhoeddwyd: (2019-07-01)

Aspirin for disease prevention: public policy or personal choice?
gan: Baigent, C
Cyhoeddwyd: (2016)

Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a)
gan: Eleni Giannopoulou, et al.
Cyhoeddwyd: (2024-12-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
gan: Mant, J, et al.
Cyhoeddwyd: (2021)

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
gan: Price, H, et al.
Cyhoeddwyd: (2009)

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
gan: Hennekens, C, et al.
Cyhoeddwyd: (1989)

Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
gan: Hennekens, C, et al.
Cyhoeddwyd: (2006)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
gan: Baigent, C, et al.
Cyhoeddwyd: (2009)

Aspirin, platelet inhibition and cancer prevention
gan: Paola Patrignani, et al.
Cyhoeddwyd: (2018-11-01)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
gan: Yinong Chen, et al.
Cyhoeddwyd: (2021-09-01)

Aspirin for prevention of cancer and cardiovascular disease.
gan: Rose, P, et al.
Cyhoeddwyd: (2011)

US population qualifying for aspirin use for primary prevention of cardiovascular disease
gan: Athena L. Huang, et al.
Cyhoeddwyd: (2024-06-01)

US POPULATION QUALIFYING FOR ASPIRIN USE FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE:
gan: Athena L. Huang, MD, et al.
Cyhoeddwyd: (2023-09-01)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
gan: Xie W, et al.
Cyhoeddwyd: (2019-09-01)

Analysis of the Dilemma Involving Statins and Aspirin as Primary Prevention Alternatives in Cardiovascular Disease
gan: Henry Sutanto
Cyhoeddwyd: (2017-10-01)

PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN DIABETES MELLITUS: THE ROLE OF ASPIRIN
gan: L. A. Strizhakov
Cyhoeddwyd: (2012-04-01)

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.
Cyhoeddwyd: (2005-12-01)

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.
gan: Randall S Stafford, et al.
Cyhoeddwyd: (2005-12-01)

2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease
gan: Xiao-Ying Li, et al.
Cyhoeddwyd: (2020-05-01)

Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease
gan: Hadar Haim-Pinhas, et al.
Cyhoeddwyd: (2022-10-01)

Aspirin use for cardiovascular disease prevention in the uninsured population
gan: Nina Liu, et al.
Cyhoeddwyd: (2020-06-01)

Coxibs, traditional NSAIDs and cardiovascular safety post-PRECISION: What we thought we knew then and what we think we know now
gan: Patrono, C, et al.
Cyhoeddwyd: (2017)

Effects of aspirin for primary prevention in persons with diabetes mellitus
gan: Bowman, L, et al.
Cyhoeddwyd: (2018)

Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification
gan: Alberto Aimo, et al.
Cyhoeddwyd: (2020-01-01)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
gan: Georg Gelbenegger, et al.
Cyhoeddwyd: (2019-11-01)

Cost‐Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease
gan: Tzeyu L. Michaud, et al.
Cyhoeddwyd: (2015-12-01)

Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
gan: Collins, R, et al.
Cyhoeddwyd: (1996)

Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease
gan: Guillaume Marquis‐Gravel, et al.
Cyhoeddwyd: (2024-02-01)

Aspirin for everyone older than 50? Against.
gan: Baigent, C
Cyhoeddwyd: (2005)

Aspirin for primary prevention of vascular disease in people with diabetes.
gan: Haynes, R, et al.
Cyhoeddwyd: (2009)